Annexon Outlines 2024 Priorities with Late-Stage Clinical Mi

08.01.2024 - ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy (GA) to Initiate Mid-2024; First ... Seite 1

Related Keywords

Brisbane , Queensland , Australia , , Nasdaq , Annexon Inc , Clinical Proof Of Concept Study , Kind Oral Small Molecule Inhibitor , Classical Pathway , First Half , Financing Extends Operating Runway , Second Quarter , Douglas Love , Report Pivotal Data , Annexon Chart , Nnexon Kurs , Nnexon Aktie ,